2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

Adarsh Bhimraj; Yngve Falck-Ytter; Arthur Y. Kim; Jonathan Z. Li; Lindsey R. Baden; Steven Johnson; Robert W. Shafer; Shmuel Shoham; Pablo Tebas; Roger Bedimo; Vincent Chi Chung Cheng; Kara W. Chew; Kathleen Chiotos; Eric S. Daar; Amy L. Dzierba; David V. Glidden; Erica J. Hardy; Greg S. Martin; Christine Macbrayne; Nandita Nadig; Mari M. Nakamura; Amy Hirsch Shumaker; Phyllis Tien; Jennifer Loveless; Rebecca L. Morgan; Rajesh T. Gandhi

doi:10.1093/cid/ciae435

2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

Adarsh Bhimraj, Yngve Falck-Ytter, Arthur Y. Kim, Jonathan Z. Li, Lindsey R. Baden, Steven Johnson, Robert W. Shafer, Shmuel Shoham, Pablo Tebas, Roger Bedimo, Vincent Chi Chung Cheng, Kara W. Chew, Kathleen Chiotos, Eric S. Daar, Amy L. Dzierba, David V. Glidden, Erica J. Hardy, Greg S. Martin, Christine Macbrayne, Nandita NadigMari M. Nakamura, Amy Hirsch Shumaker, Phyllis Tien, Jennifer Loveless, Rebecca L. Morgan, Rajesh T. Gandhi

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of the anti-severe acute respiratory syndrome coronavirus 2 neutralizing antibody pemivibart as pre-exposure prophylaxis. The recommendation is based on evidence derived from a systematic review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Information on pemivibart is included in the U.S. Food and Drug Administration Emergency Use Authorization for this agent.

Original language	English (US)
Pages (from-to)	i6-i12
Journal	Clinical Infectious Diseases
Volume	81
DOIs	https://doi.org/10.1093/cid/ciae435
State	Published - Oct 15 2025

Keywords

COVID-19
SARS-CoV-2
guideline
pemivibart
pre-exposure prophylaxis

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciae435

Cite this

Bhimraj, A., Falck-Ytter, Y., Kim, A. Y., Li, J. Z., Baden, L. R., Johnson, S., Shafer, R. W., Shoham, S., Tebas, P., Bedimo, R., Cheng, V. C. C., Chew, K. W., Chiotos, K., Daar, E. S., Dzierba, A. L., Glidden, D. V., Hardy, E. J., Martin, G. S., Macbrayne, C., ... Gandhi, R. T. (2025). 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clinical Infectious Diseases, 81, i6-i12. https://doi.org/10.1093/cid/ciae435

2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. / Bhimraj, Adarsh; Falck-Ytter, Yngve; Kim, Arthur Y. et al.
In: Clinical Infectious Diseases, Vol. 81, 15.10.2025, p. i6-i12.

Research output: Contribution to journal › Article › peer-review

Bhimraj, A, Falck-Ytter, Y, Kim, AY, Li, JZ, Baden, LR, Johnson, S, Shafer, RW, Shoham, S, Tebas, P, Bedimo, R, Cheng, VCC, Chew, KW, Chiotos, K, Daar, ES, Dzierba, AL, Glidden, DV, Hardy, EJ, Martin, GS, Macbrayne, C, Nadig, N, Nakamura, MM, Shumaker, AH, Tien, P, Loveless, J, Morgan, RL & Gandhi, RT 2025, '2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis', Clinical Infectious Diseases, vol. 81, pp. i6-i12. https://doi.org/10.1093/cid/ciae435

@article{00d253a060bf4a92ab2bfd0dd5adbb5a,

title = "2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis",

abstract = "This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of the anti-severe acute respiratory syndrome coronavirus 2 neutralizing antibody pemivibart as pre-exposure prophylaxis. The recommendation is based on evidence derived from a systematic review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Information on pemivibart is included in the U.S. Food and Drug Administration Emergency Use Authorization for this agent.",

keywords = "COVID-19, SARS-CoV-2, guideline, pemivibart, pre-exposure prophylaxis",

author = "Adarsh Bhimraj and Yngve Falck-Ytter and Kim, \{Arthur Y.\} and Li, \{Jonathan Z.\} and Baden, \{Lindsey R.\} and Steven Johnson and Shafer, \{Robert W.\} and Shmuel Shoham and Pablo Tebas and Roger Bedimo and Cheng, \{Vincent Chi Chung\} and Chew, \{Kara W.\} and Kathleen Chiotos and Daar, \{Eric S.\} and Dzierba, \{Amy L.\} and Glidden, \{David V.\} and Hardy, \{Erica J.\} and Martin, \{Greg S.\} and Christine Macbrayne and Nandita Nadig and Nakamura, \{Mari M.\} and Shumaker, \{Amy Hirsch\} and Phyllis Tien and Jennifer Loveless and Morgan, \{Rebecca L.\} and Gandhi, \{Rajesh T.\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s).",

year = "2025",

month = oct,

day = "15",

doi = "10.1093/cid/ciae435",

language = "English (US)",

volume = "81",

pages = "i6--i12",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19

T2 - Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

AU - Bhimraj, Adarsh

AU - Falck-Ytter, Yngve

AU - Kim, Arthur Y.

AU - Li, Jonathan Z.

AU - Baden, Lindsey R.

AU - Johnson, Steven

AU - Shafer, Robert W.

AU - Shoham, Shmuel

AU - Tebas, Pablo

AU - Bedimo, Roger

AU - Cheng, Vincent Chi Chung

AU - Chew, Kara W.

AU - Chiotos, Kathleen

AU - Daar, Eric S.

AU - Dzierba, Amy L.

AU - Glidden, David V.

AU - Hardy, Erica J.

AU - Martin, Greg S.

AU - Macbrayne, Christine

AU - Nadig, Nandita

AU - Nakamura, Mari M.

AU - Shumaker, Amy Hirsch

AU - Tien, Phyllis

AU - Loveless, Jennifer

AU - Morgan, Rebecca L.

AU - Gandhi, Rajesh T.

PY - 2025/10/15

Y1 - 2025/10/15

N2 - This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of the anti-severe acute respiratory syndrome coronavirus 2 neutralizing antibody pemivibart as pre-exposure prophylaxis. The recommendation is based on evidence derived from a systematic review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Information on pemivibart is included in the U.S. Food and Drug Administration Emergency Use Authorization for this agent.

AB - This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of the anti-severe acute respiratory syndrome coronavirus 2 neutralizing antibody pemivibart as pre-exposure prophylaxis. The recommendation is based on evidence derived from a systematic review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Information on pemivibart is included in the U.S. Food and Drug Administration Emergency Use Authorization for this agent.

KW - COVID-19

KW - SARS-CoV-2

KW - guideline

KW - pemivibart

KW - pre-exposure prophylaxis

UR - https://www.scopus.com/pages/publications/105010377305

UR - https://www.scopus.com/inward/citedby.url?scp=105010377305&partnerID=8YFLogxK

U2 - 10.1093/cid/ciae435

DO - 10.1093/cid/ciae435

M3 - Article

C2 - 39471458

AN - SCOPUS:105010377305

SN - 1058-4838

VL - 81

SP - i6-i12

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

ER -

2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this